HumaPen Ergo®: A new 3.0ml Reusable insulin pen evaluation of patient acceptability

Clinical Drug Investigation

Volumn 21, Issue 5, 2001, Pages 319-324

  Stocks, Alan ^a   Perry, S R ^a   Brydon, P ^b  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b ELI LILLY AUSTRALIA PTY LTD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAPEN ERGO; NEUTRAL INSULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CLINICAL TRIAL; DISEASE DURATION; DOSE RESPONSE; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL;

EID: 0035024684     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121050-00001     Document Type: Article

References (5)

1. The Diabetes Control And Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
2. Leading Article. Insulin pen; mightier than syringe? Lancet 1989; 1: 307-8
3. Holmwood C, Phillips P. Insulin and type 2 diabetes. Last resort or rational management? Aust Fam Physician 1999; 28: 429-35
4. Stocks AE. What is new in insulin delivery systems. Curr Ther 1995; 36: 109-11
5. Martin JM, Llewellyn JA, Ristic S, et al. Acceptability and safety of a new 3.0ml re-usable insulin pen (HumaPen®) in clinical use. Diab Nutr Metab 1999; 12: 306-9